Aparna Kalyan

2.9k total citations
66 papers, 2.1k citations indexed

About

Aparna Kalyan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Aparna Kalyan has authored 66 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Oncology, 18 papers in Pulmonary and Respiratory Medicine and 16 papers in Cancer Research. Recurrent topics in Aparna Kalyan's work include Pancreatic and Hepatic Oncology Research (17 papers), Colorectal Cancer Treatments and Studies (14 papers) and Cancer Immunotherapy and Biomarkers (14 papers). Aparna Kalyan is often cited by papers focused on Pancreatic and Hepatic Oncology Research (17 papers), Colorectal Cancer Treatments and Studies (14 papers) and Cancer Immunotherapy and Biomarkers (14 papers). Aparna Kalyan collaborates with scholars based in United States, Philippines and South Korea. Aparna Kalyan's co-authors include Young Kwang Chae, Mary F. Mulcahy, Benedito A. Carneiro, Al B. Benson, Francis J. Giles, Sheetal Kircher, Jason Kaplan, Sunandana Chandra, Halla Nimeiri and Leonidas C. Platanias and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Journal of the American College of Cardiology.

In The Last Decade

Aparna Kalyan

63 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Aparna Kalyan United States	26	1.1k	802	550	523	486	66	2.1k
Kristen K. Ciombor United States	21	1.2k 1.0×	458 0.6×	357 0.6×	307 0.6×	383 0.8×	90	1.7k
Yuan‐Tzu Lan Taiwan	30	1.5k 1.3×	814 1.0×	680 1.2×	544 1.0×	833 1.7×	108	2.6k
Daniela Kandioler Austria	23	835 0.7×	622 0.8×	351 0.6×	529 1.0×	350 0.7×	55	1.7k
Denis L. Jardim Brazil	21	1.1k 0.9×	625 0.8×	203 0.4×	619 1.2×	671 1.4×	63	2.0k
Andrea Coinu Italy	21	1.3k 1.2×	394 0.5×	603 1.1×	553 1.1×	772 1.6×	36	2.2k
Enrico Vasile Italy	27	1.8k 1.6×	1.0k 1.3×	599 1.1×	1.1k 2.0×	883 1.8×	147	2.9k
Megumi Ishiguro Japan	27	1.4k 1.2×	509 0.6×	608 1.1×	301 0.6×	555 1.1×	103	2.1k
Changping Wu China	25	1.3k 1.1×	673 0.8×	309 0.6×	599 1.1×	508 1.0×	58	2.4k
Toshihiro Kudo Japan	21	836 0.7×	533 0.7×	383 0.7×	438 0.8×	420 0.9×	86	1.5k
Morten Mau‐Sørensen Denmark	28	1.2k 1.1×	1.1k 1.4×	252 0.5×	541 1.0×	527 1.1×	130	2.7k

Countries citing papers authored by Aparna Kalyan

Since Specialization

Citations

This map shows the geographic impact of Aparna Kalyan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aparna Kalyan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aparna Kalyan more than expected).

Fields of papers citing papers by Aparna Kalyan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aparna Kalyan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aparna Kalyan. The network helps show where Aparna Kalyan may publish in the future.

Co-authorship network of co-authors of Aparna Kalyan

This figure shows the co-authorship network connecting the top 25 collaborators of Aparna Kalyan. A scholar is included among the top collaborators of Aparna Kalyan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aparna Kalyan. Aparna Kalyan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dotan, Efrat, Paul J. Catalano, Leon Lenchik, et al.. (2025). Effect of baseline geriatric and quality of life assessments on treatment outcomes in ECOG-ACRIN EA2186 (GIANT): A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer.. Journal of Clinical Oncology. 43(4_suppl). 676–676.

Dotan, Efrat, Paul J. Catalano, Leon Lenchik, et al.. (2024). A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186.. Journal of Clinical Oncology. 42(16_suppl). 4003–4003. 4 indexed citations

Gordon, Andrew C., Ahmed Gabr, Aparna Kalyan, et al.. (2024). Radiation Segmentectomy and Modified Radiation Lobectomy for Unresectable Early-Stage Intrahepatic Cholangiocarcinoma. Journal of Vascular and Interventional Radiology. 36(4). 650–659. 1 indexed citations

Davis, Andrew A., Ecaterina E. Dumbrava, Aparna Kalyan, et al.. (2024). Abstract CT159: Phase I trial of trastuzumab deruxtecan in combination with neratinib in solid tumors with HER2 alterations (NCI 10495). Cancer Research. 84(7_Supplement). CT159–CT159. 1 indexed citations

Mahalingam, Devalingam, Siqi Chen, Ping Xie, et al.. (2023). Combination of pembrolizumab and pelareorep promotes anti-tumour immunity in advanced pancreatic adenocarcinoma (PDAC). British Journal of Cancer. 129(5). 782–790. 12 indexed citations

Snyder, Rebecca A., Barbara Burtness, May Cho, et al.. (2023). The room where it happens: addressing diversity, equity, and inclusion in National Clinical Trials Network clinical trial leadership. JNCI Journal of the National Cancer Institute. 115(10). 1132–1138. 2 indexed citations

Kalyan, Aparna, et al.. (2022). Immunotherapy in Biliary Tract Cancers: Where Are We?. Current Oncology Reports. 24(12). 1821–1828. 7 indexed citations

Gordon, Andrew C., Ahmed Gabr, Aparna Kalyan, et al.. (2022). Yttrium-90 Radioembolization of Unresectable Intrahepatic Cholangiocarcinoma: Long-Term Follow-up for a 136-Patient Cohort. CardioVascular and Interventional Radiology. 45(8). 1117–1128. 13 indexed citations

Fenton, Sarah E., Michael C. Burns, & Aparna Kalyan. (2021). Epidemiology, mutational landscape and staging of hepatocellular carcinoma. Chinese Clinical Oncology. 10(1). 2–2. 12 indexed citations

10.

Wainberg, Zev A., Howard S. Höchster, Edward Kim, et al.. (2019). Phase I study of nivolumab (Nivo) + nab-paclitaxel (nab-P) + gemcitabine (Gem) in advanced pancreatic cancer (APC).. Journal of Clinical Oncology. 37(4_suppl). 298–298. 27 indexed citations

11.

Sahai, Vaibhav, Aparna Kalyan, Philip A. Philip, et al.. (2019). A Phase I/II Open-Label Multicenter Single-Arm Study of FABLOx (Metronomic 5-Fluorouracil Plus nab -Paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin) in Patients with Metastatic Pancreatic Cancer. SHILAP Revista de lepidopterología. 5(1). 35–42. 11 indexed citations

12.

Kamath, Suneel D., Aparna Kalyan, Sheetal Kircher, et al.. (2019). Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study. The Oncologist. 25(5). e808–e815. 147 indexed citations

13.

Kalyan, Aparna, Sheetal Kircher, Hiral Shah, Mary F. Mulcahy, & Al B. Benson. (2018). Updates on immunotherapy for colorectal cancer. Journal of Gastrointestinal Oncology. 9(1). 160–169. 123 indexed citations

14.

Picozzi, Vincent J., Vaibhav Sahai, Diane M. Simeone, et al.. (2017). A phase 1/2 study of metronomic 5-fluorouracil (5-FU) plus nab-paclitaxel, bevacizumab, leucovorin, and oxaliplatin (FABLOx) in patients with metastatic pancreatic cancer. Annals of Oncology. 28. iii81–iii82. 1 indexed citations

15.

Hickey, Ryan, Laura Kulik, Halla Nimeiri, et al.. (2017). Immuno-oncology and Its Opportunities for Interventional Radiologists: Immune Checkpoint Inhibition and Potential Synergies with Interventional Oncology Procedures. Journal of Vascular and Interventional Radiology. 28(11). 1487–1494. 27 indexed citations

16.

Wainberg, Zev A., Howard S. Höchster, Ben George, et al.. (2017). Phase I study of nivolumab (nivo) + nab-paclitaxel (nab-P) ± gemcitabine (Gem) in solid tumors: Interim results from the pancreatic cancer (PC) cohorts.. Journal of Clinical Oncology. 35(4_suppl). 412–412. 25 indexed citations

17.

Bridgewater, John, Karyn A. Goodman, Aparna Kalyan, & Mary F. Mulcahy. (2016). Biliary Tract Cancer: Epidemiology, Radiotherapy, and Molecular Profiling. American Society of Clinical Oncology Educational Book. 35(36). e194–e203. 149 indexed citations

18.

Sahai, Vaibhav, et al.. (2016). P-286 Metronomic 5-fluorouracil (5-FU) plus nab-paclitaxel (nab-P), bevacizumab, leucovorin, and oxaliplatin (FABLOx) in patients with metastatic pancreatic cancer (MPC): an open-label, multicenter, single-arm, phase 1/2 study. Annals of Oncology. 27. ii83–ii83. 4 indexed citations

19.

Chae, Young Kwang, Su Yun Chung, Andrew A. Davis, et al.. (2015). Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling. Oncotarget. 6(35). 37117–37134. 79 indexed citations

20.

Villaruz, Liza C., Aparna Kalyan, Hassane M. Zarour, & Mark A. Socinski. (2014). Immunotherapy in lung cancer.. PubMed. 3(1). 2–14. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact